top of page

William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026

  • blonca9
  • Dec 30, 2025
  • 1 min read

He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.




Chapters

Wegovy in a pill - 1:04

Lilly’s pill orforglipron - 9:14

Structure’s pill aleniglipron - 13:13

Lilly’s retatrutide - 16:33

Amylins (Zealand and others) - 19:47

Corbus’ CB1 inverse agonist – 24:53

Viking - 28:02

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page